One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B infection post-liver transplantation

Tomohiro Tanaka MD1,2, Eberhard L Renner MD2, Nazia Selzner MD PhD1, George Therapondos MD2, Leslie B Lilly MD1


BACKGROUND: Hepatitis B immunoglobulin (HBIG) given in combination with a nucleos(t)ide analogue has reduced the rate of recurrent hepatitis B virus (HBV) infection following liver transplantation (LT); however, the most effective protocol remains unclear.

OBJECTIVE: To evaluate the use of tenofovir disoproxil fumarate (TDF) in combination with one year of low-dose HBIG.

METHODS: Twenty-four adults who underwent LT for HBV-related liver disease at the University Health Network (Toronto, Ontario) and received TDF (± lamivudine) and one year of HBIG to prevent recurrent HBV infection from June 2005 to June 2011 were evaluated.

RESULTS: The median length of follow-up post-LT was 29.1 months. Three patients died during the follow-up period. Patient survival was 100% and 84.1% at one and five years, respectively. None of the patients developed recurrent HBV infection. No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved.

CONCLUSION: The present study demonstrated that a short, finite course of low-dose HBIG combined with maintenance of long-term TDF staring before LT is cost-effective and safe. However, further prospective study involving a larger patient cohort with a longer follow-up period is required to confirm the results.

Key Words: HBIG; Hepatitis B; Liver transplantation; Tenofovir

Strategies to prevent recurrent hepatitis B virus (HBV) infection post-liver transplantation (LT) have been advancing since the introduction of hepatitis B immunoglobulin (HBIG) and lamivudine (LAM). The recurrence rate without treatment was reported to be approximately 80% (1), but has decreased to <10% with the use of HBIG plus LAM in combination (2-5). Nevertheless, the high cost of HBIG (6), its limited availability in some regions or countries, and inconvenient mode of administration have limited the broad use of combination regimens. The potential risk of transmitted infections with the use of HBIG cannot be overlooked. In an attempt to minimize the use of HBIG, we recently published a study describing the feasibility of a short, finite course of HBIG of 12 months, mainly in combination with long-term use of LAM (7).

However, the long-term use of HBIG has been recommended to introduce high rates of resistance to the drug in both LT and NLT settings due to mutations or amino acid substitutions in the conserved tyr-met-asp-asp (YMDD) motif (8). With its potent antiviral activity and barrier to the development of resistance, tenofovir disoproxil fumarate (TDF) has been recognized as one of the first drugs to suppress HBV without the risk of resistance, which may result in progression to decompensated liver cirrhosis (9,10). A recent study (11) demonstrated the safety and efficacy of TDF for patients with decompensated liver cirrhosis, although information regarding TDF administration in LT settings remains scarce.

We conducted the current study to evaluate the efficacy and safety of TDF in combination with one-year of low-dose HBIG as prophylaxis for recurrent HBV infection post-LT.

METHODS

Patients and antiviral prophylaxis protocol

A prospectively maintained institutional database of transplant patients (Organ Transplant Tracking Record [OTTR], HKS Medical Information Systems, USA), an internal transplantation database linked to the electronic medical record of all patients evaluated for a solid organ transplant at the University Health Network, Toronto, Ontario) was used to identify all adults (≥18 years of age) who received low-dose HBIG for one year combined with maintenance TDF (or LAM plus TDF) to prevent recurrent HBV infection post-LT for HBV-related
end-stage liver disease from May 2005 to June 2011, with follow-up through June 2012 or death. Patients who were started on TDF to treat recurrent HBV infection post-LT were not included. Patient data were collected retrospectively via the OTTR database. The primary end point of the present study was overall survival; the secondary end point was the recurrence rates of HBV infection following LT, defined as the appearance of positive hepatitis B surface antigen (HBsAg) and detectable serum HBV DNA post-LT.

**HBV prophylaxis regimen**

Since 1999, all patients undergoing LT for HBV-related end-stage liver disease have been protocolized to continue the nucleotide analogue (NA) on which they were pretransplant, or to introduce the NA (LAM until 2007, and entecavir [ETV] or TDF since 2008) immediately post-LT for patients who were not on any NAs pre-LT, along with one year of HBIG: first dose of HBIG (2000 IU) given intravenously during the anhepatic phase, followed by a daily dose for seven days (intravenously, then intramuscularly), then weekly three times, then monthly 11 times (7). The dose of TDF was based on guideline recommendations from the American Association for the Study of Liver Diseases (9).

**Immunosuppression**

Maintenance immunosuppression consisted of a double- or triple-drug regimen that included tacrolimus, cyclosporine or rapamycin, and prednisone, with or without mycophenolate mofetil. Prednisone was generally planned to be withdrawn within the first four months (it was withdrawn in almost all patients within 12 months of LT). Tacrolimus and rapamycin were monitored according to trough levels, and cyclosporine according to blood concentration level at 2 h postdose (C2). Some patients received induction therapy, including basiliximab, thymoglobulin or rabbit antithymocyte globulin, generally for renal- or neurological-sparing purposes, primarily to delay the introduction of calcineurin inhibitors (7).

**HBV evaluation**

Regarding HBV evaluation pre-LT, viral markers, including HBsAg, hepatitis B surface antibody (HBsAb), hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb) and hepatitis B core antibody, were measured using standard commercial assays (Abbott Laboratories, USA). HBV DNA levels were measured using real-time polymerase chain reaction (Cobas TaqMan, Roche Molecular Systems, USA). Following LT, HBV DNA and HBsAg levels were measured every three months for the first year, and then every six months thereafter. In contrast to earlier studies, the titres of HBsAb were not measured; hence, HBIG dosing was not adjusted.

**TABLE 1**

**Patient characteristics**

<table>
<thead>
<tr>
<th>Age, years, median (range)</th>
<th>54 (23–65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>22 (92)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>12 (50)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>8 (33)</td>
</tr>
<tr>
<td>Others</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Indication</td>
<td></td>
</tr>
<tr>
<td>Chronic liver failure</td>
<td>7 (29)</td>
</tr>
<tr>
<td>Acute on chronic liver failure</td>
<td>3 (13)</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>14 (58)</td>
</tr>
<tr>
<td>HBeAg pretransplantation (+)</td>
<td>8 (33)</td>
</tr>
<tr>
<td>HBV DNA pretransplantation &lt;2.1 log copies/mL</td>
<td>12 (50)</td>
</tr>
<tr>
<td>Living donor liver transplantation</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Use of induction therapy*</td>
<td>8 (33)</td>
</tr>
<tr>
<td>Post-transplant prednisone withdrawal time &gt;4 months</td>
<td>7 (29)</td>
</tr>
</tbody>
</table>

Data presented as n (%) unless otherwise indicated. *Three with thymoglobulin and five with basiliximab. HBeAg Hepatitis B e antigen; HBV Hepatitis B virus

![Figure 1](Image)

**Figure 1** Cumulative survival rate of patients receiving tenofovir disoproxil fumarate (± lamivudine) in combination with one year of hepatitis B immunoglobulin (n=24) to prevent recurrent hepatitis B post-liver transplantation (LT)

**Statistical analysis**

SPSS version 17.0 (IBM Corporation, USA) was used to analyze the relevant data. Continuous variables are summarized as mean ± SD, or median and range, whereas categorical variables are presented as proportions. The Student’s t test, Fisher’s exact test or ANOVA were used for group comparisons as appropriate. Overall survival was calculated using the Kaplan-Meier method; P<0.05 was considered to be statistically significant.

**RESULTS**

Twenty-four patients received one year of HBIG in combination with TDF-based NA as a prophylaxis for recurrent HBV infection: 15 with TDF and nine with LAM + TDF were identified. In the nine patients who received LAM + TDF in combination with HBIG, TDF had been added to LAM for breakthrough hepatitis before LT. None of the 24 patients were coinfected with hepatitis C virus, hepatitis D virus or HIV. The median post-LT follow-up period was 29.1 months (range 12.5 to 85.5 months). Of the 24 patients, 16 (67%) had hepatocellular carcinoma (HCC), of whom five (31%) were beyond the Milan criteria at LT. During the follow-up period, three patients (two within Milan criteria and one beyond Milan criteria) developed recurrent HCC. Other clinical demographic data regarding the 24 patients in the present study are summarized in Table 1.

**Overall survival**

Three patients died during the follow-up period: two with recurrent HCC (14.7 and 18.4 months post-LT) and one with chronic rejection (23.5 months post-LT). None of the deceased patients experienced recurrent HBV infection. Overall patient survival calculated by Kaplan-Meier analysis was 100% and 84.1% at one and five years post-LT, respectively (Figure 1).

**HBV recurrence**

None of the 24 patients developed recurrent HBV infection in the median follow-up period of 29.1 months. Neither HBsAg nor HBV DNA levels became detectable during the follow-up period.

**Safety of prophylaxis with TDF plus one year of HBIG**

No adverse events were observed in the study group due to TDF administration. Regarding renal function, the median serum creatinine level and
estimated creatinine clearance (CCr) by Modification of Diet in Renal Disease (MDRD) equation at LT were 85.3 µmol/L and 85.5 mL/min, respectively. There were no statistically significant changes in serum creatinine level or estimated CCr by MDRD equation during the follow-up period (Table 2).

DISCUSSION

In the current study, LT recipients who underwent the prophylaxis regimen consisting of indefinite TDF in combination with low-dose HBIG for one year showed a five-year survival rate of approximately 85%. None of the 24 patients developed recurrent HBV infection with the prophylaxis regimen during the median follow-up period of 29.1 months. No significant adverse events related to TDF were observed. In addition, no patients experienced significantly impaired renal function.

The administration of HBIG and NA, especially when used in combination, has drastically reduced the post-LT HBV recurrence rate (5). However, the optimal timing to discontinue HBIG and choice of NA remain uncertain. There have been several reports citing the safety of an HBIG-free regimen (12-14). We previously reported the feasibility of finite use of HBIG post-LT for HBV-related disease; however, the rate of recurrent HBV infection was suboptimal (approximately 8.6% at five years post-LT), probably because LAM was predominantly used in the study group (7). We concluded in the report that one year of HBIG would be more acceptable when used with a more potent NA, such as TDF, which has been well recognized as one of the first choices to treat hepatitis B (9,10).

To date, several published studies have described the efficacy and safety of TDF in LT recipients (15-19). However, two included a relatively small number of patients (n=3 [15] and n=4 [16]). Stravitz et al (17) reported that the combination of TDF and entecavir was successfully switched from HBIG plus NA (ETV, LAM and/or adefovir) in 21 patients, although 14% of them developed detectable HBsAg levels after conversion to the drug. Similarly, Cholongitas et al (18) reported that 15 patients who received TDF as a substitute to the regimen of non-TDF NA plus HBIG did not experience clinical manifestations of recurrent HBV infection, although one-third of the patients were coinfected with hepatitis D virus, which has been reported to reduce the risk of recurrent hepatitis B (20). Importantly, the prospective phase 2 randomized study published by Teperman et al (19) in 2013 compared recipients of TDF + entecavir in combination with indefinite HBIG (n=19) and those with TDF + emtricitabine with HBIG for 24 weeks only (n=18), as prophylaxis for HBV recurrence. They reported that none of the randomized groups experienced HBV recurrence during the follow-up period of 72 weeks. All of these studies concluded that the safety of administering TDF in this setting was well preserved. In the current study, TDF was continued before LT in combination with a short course of low-dose HBIG post-LT. In addition to the reduced cost and risk of transmitted infection from cessation of HBIG at one year post-LT, this regimen has satisfactorily suppressed HBV in these 24 patients, with no HBV recurrence during the median follow-up period of 29.1 months.

The potential renal toxicity of TDF remains a significant concern, especially in patients with decompensated liver disease and post-LT. In the current study cohort, the estimated CCr by MDRD was acceptable (mean 85.5 mL/min). In addition, even after LT, renal function did not change significantly up to the latest follow up, although the estimated CCr by MDRD appeared to trend downward, likely due to the administration of calcineurin inhibitors post-LT.

The present retrospective study had several limitations. The size of the study population was small and the follow-up period was relatively short. In addition, our regimen still contains HBIG, which could be safely avoided when newer NAs, such as ETV (12) or TDF, were administered. Another study is strongly warranted to confirm the efficacy and safety of TDF monotherapy as prophylaxis for recurrent HBV infection.

CONCLUSION

Our study demonstrated the satisfactory efficacy and safety of a regimen consisting of one year of HBIG and TDF (+ LAM) to prevent recurrent HBV infection post-LT in HBV-related liver disease. The general discontinuation of HBIG, especially when newer, potent NAs (TDF in the present study) are administered, showed acceptable overall survival and HBV recurrence rate in our patient cohort, although larger prospective study with a longer follow-up period should be conducted to confirm the result. In addition, the great challenge not to initiate HBIG but to maintain newer potent NAs, such as TDF or ETV alone, should be tested in future studies.

DISCLOSURES: This study was not funded. This manuscript was not prepared nor funded in any part by a commercial organization. None of the authors have any conflict of interest to declare with regard to the content of this article.

ACKNOWLEDGEMENT: The authors are grateful to Drs Sandra Fischer, Maha Gundi and Oyedele Adeyi for their contribution to the histological examination of the liver biopsies.

REFERENCES


